WuXi Biologics (Cayman)

Latest news

• 
  Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption (opens in a new tab)

  GlobeNewswire · Oct 1, 2026

• 
  WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability (opens in a new tab)

  PR Newswire · Sep 24, 2026

• Wuxi Biologics (Cayman) Stock Slips 1.7% in Hong Kong (opens in a new tab)

  富途牛牛 · Sep 24, 2026

• 
  WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership (opens in a new tab)

  PR Newswire · Sep 16, 2026

• 
  Big Pharma Is Pouring Billions Into China’s Biotechs (opens in a new tab)

  Sep 14, 2026

• 
  WuXi Biologics Reports Strong Profitable Growth in H1 2026 (opens in a new tab)

  PR Newswire · Aug 25, 2026

• 
  WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO (opens in a new tab)

  PR Newswire · Aug 18, 2026

• 
  Is WuXi Biologics (Cayman) (SEHK:2269) Still Below Fair Value On FTSE4Good Recognition? (opens in a new tab)

  Simply Wall St. · Jul 31, 2026

• 
  WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO (opens in a new tab)

  PR Newswire · Jul 29, 2026

• 
  WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy (opens in a new tab)

  PR Newswire · Jul 9, 2026

• 
  WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year (opens in a new tab)

  PR Newswire · Jul 8, 2026

• 
  WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy (opens in a new tab)

  PR Newswire · Jun 30, 2026

• WuXi Biologics on target for 2028 opening in Worcester (opens in a new tab)

  Jun 29, 2026

• 
  WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations (opens in a new tab)

  PR Newswire · Jun 24, 2026

• 
  WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards (opens in a new tab)

  PR Newswire · Jun 8, 2026

• WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility (opens in a new tab)

  Jun 5, 2026

• WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year (opens in a new tab)

  Jun 3, 2026

• WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing (opens in a new tab)

  May 26, 2026

• WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index (opens in a new tab)

  May 13, 2026

• Assessing WuXi Biologics (SEHK:2269) Valuation After Recent Share Price Weakness (opens in a new tab)

  May 11, 2026